ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-mutCALR/Anti-CD3 Bispecific Antibody INCA035784

Its studies are mostly in Myeloproliferative Disorders, led by Incyte.

Furthest: phase 1, since May 29, 20251 company-led study, 1 open or runningNext primary completion: Mar 14, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte11 open or runningphase 1since May 29, 2025May 29, 2025Mar 14, 2028phase 1 · NCT07008118

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2025First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT07008118 · 120 planned · United States, Australia, Belgium and more

Ahead

  1. Mar 14, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT07008118

TargetBeta

CD3E →read by rule
“A human Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody directed against both the mutated form of calreticulin (mutCALR; CALRmut) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
ramantamigJohnson & Johnsonphase 38
cevostamabHoffmann-La Rochephase 38
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07008118Myeloproliferative Disorders · United States, Australia, Belgium and more1RecruitingMar 14, 2028120

How it is read

Names in the registry

  • “INCA035784”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.